Serina Therapeutics, Inc.SEREarnings & Financial Report
NYSE
SER Q3 2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-6.4M
Net Profit
$-4.6M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.45
Serina Therapeutics, Inc. Q3 2025 Financial Summary
Serina Therapeutics, Inc. reported revenue of $0 for Q3 2025, with a net profit of $-4.6M (N/A margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-4.6M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 2025 |
Serina Therapeutics, Inc. Annual Revenue by Year
Serina Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $56.0K).
| Year | Annual Revenue |
|---|---|
| 2024 | $56.0K |
| 2023 | $142.0K |
| 2022 | $34.0K |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $56000 | $5000 | $51000 | $14000 | $-14000 | $0 | $130000 | $0 |
| YoY Growth | 600.0% | -50.0% | 466.7% | -79.1% | -125.0% | N/A | 154.9% | N/A |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $12.0M | $10.9M | $10.7M | $7.4M | $6.7M | $6.7M | $8.9M | $12.4M |
| Liabilities | $6.6M | $15.2M | $27.1M | $21.3M | $6.2M | $5.2M | $7.3M | $10.8M |
| Equity | $5.5M | $-4.3M | $-16.4M | $-13.8M | $641000 | $1.7M | $1.8M | $1.8M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-2.1M | $-1.6M | $-8.0M | $-3.0M | $-4.6M | $-4.3M | $-3.8M | $-3.9M |